Resource impact statement
Cancer Drugs Fund technology
NICE has recommended daratumumab for use within the Cancer Drugs Fund as an option for treating relapsed and refractory multiple myeloma in adults whose previous therapy included a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last therapy, only if they have daratumumab after 3 previous therapies.
Daratumumab will be available to the NHS in line with the managed access agreement with NHS England. As part of this, NHS England and Janssen have agreed a commercial access agreement that makes daratumumab available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.
The resource impact of daratumumab will be covered by the Cancer Drugs Fund budget. The guidance on this technology will be considered for review by NICE 3 years after publication of the guidance. NICE will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators. The aim of the review is to decide whether or not the drug can be recommended for routine use. Further information can be found in NHS England’s Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) - A new deal for patients, taxpayers and industry.
It is estimated that 700 people per year with relapsed and refractory multiple myeloma are eligible for treatment with daratumumab.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: 14 March 2018